In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ilaris Complete Response Letter Raises Questions About The Validity of Priority Review Vouchers

Executive Summary

What’s a Priority Review Voucher worth? That’s a complicated question now that the first voucher used on an application, from drug maker Novartis AG for Ilaris (canakinumab), has received a complete response letter from US regulators.
Advertisement

Related Content

Novartis Takes Stock Of Ilaris For Gout Following FDA's Complete Response Letter
How Much Is A Priority Review Voucher Worth? Perhaps $387 Mil.
Priority Review Voucher's Uncertain Value May Hinder Development
Placing Value on FDA's Priority Review Vouchers
Placing Value on FDA's Priority Review Vouchers
Treat and Trade: The New Priority Review Voucher Market

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003701

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel